Gainers

• AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out 2 days ago.
• NextCure (NASDAQ:NXTC) shares rose 7.87% to $6.3. The company's market cap stands at $22.7 million. The company's, Q2 earnings came out yesterday.
• SILO Pharma (NASDAQ:SILO) stock increased by 7.09% to $4.0. The company's market cap stands at $5.2 million.
• BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 6.61% to $0.22. The market value of their outstanding shares is at $5.3 million.
• Akanda (NASDAQ:AKAN) shares increased by 5.65% to $5.42. The market value of their outstanding shares is at $2.8 million.
• Vyome Holdings (NASDAQ:HIND) shares moved upwards by 5.52% to $2.29. The company's market cap stands at $15.0 million.

Losers

• Silexion Therapeutics (NASDAQ:SLXN) shares declined by 13.4% to $1.62 during Friday's after-market session. The market value of their outstanding shares is at $1.9 million.
• Matinas BioPharma Hldgs (AMEX:MTNB) shares fell 9.97% to $0.25. The company's market cap stands at $1.7 million.
• Icecure Medical (NASDAQ:ICCM) shares declined by 8.77% to $2.81. The company's market cap stands at $10.5 million.
• NuCana (NASDAQ:NCNA) stock decreased by 8.17% to $1.35. The company's market cap stands at $5.6 million.
• Radiopharm Theranostics (NASDAQ:RADX) shares fell 7.15% to $2.6. The company's market cap stands at $21.7 million.
• Imunon (NASDAQ:IMNN) shares declined by 6.84% to $1.5. The market value of their outstanding shares is at $6.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.